Literature DB >> 8221087

Ephedrine: effects on neuromuscular transmission.

J P Sieb1, A G Engel.   

Abstract

(-)-Ephedrine has been used in the treatment of patients with myasthenia gravis. To investigate the possible effects of ephedrine on neuromuscular transmission, canine intercostal muscle endplates were studied by microelectrode techniques. At concentrations less than 10(-4) M, ephedrine had no effect on neuromuscular transmission. At a concentration of 10(-4) M, ephedrine increased the quantal content of the endplate potential by 21%. The presynaptic store of acetylcholine quanta available for immediate release was unchanged, but the probability of quantal release was increased by 16%. At this concentration, ephedrine decreased the amplitude of the miniature endplate potential by 38%. In the presence of 10(-3) M ephedrine, the miniature endplate potentials and currents became undetectable. The kinetic properties of the acetylcholine receptor channel were studied by analysis of acetylcholine-induced endplate current noise. At 10(-4) M, ephedrine reduced the channel conductance by 43% but had no effect on the open time. At 5 x 10(-4) M, ephedrine reduced the channel conductance by 84% and increased the open time by 23 percent.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8221087     DOI: 10.1016/0006-8993(93)90025-i

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  13 in total

1.  Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7.

Authors:  D Lashley; J Palace; S Jayawant; S Robb; D Beeson
Journal:  Neurology       Date:  2010-05-11       Impact factor: 9.910

2.  Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and Dok-7 myasthenia.

Authors:  Teerin Liewluck; Duygu Selcen; Andrew G Engel
Journal:  Muscle Nerve       Date:  2011-09-23       Impact factor: 3.217

3.  Salbutamol modifies the neuromuscular junction in a mouse model of ColQ myasthenic syndrome.

Authors:  Grace M McMacken; Sally Spendiff; Roger G Whittaker; Emily O'Connor; Rachel M Howarth; Veronika Boczonadi; Rita Horvath; Clarke R Slater; Hanns Lochmüller
Journal:  Hum Mol Genet       Date:  2019-07-15       Impact factor: 6.150

4.  The potential use of ephedrine in Lambert-Eaton myasthenic syndrome : clinical and electrophysiological evaluation.

Authors:  Carlo Cereda; Thierry Kuntzer
Journal:  J Neurol       Date:  2008-06-13       Impact factor: 4.849

Review 5.  The rush to adrenaline: drugs in sport acting on the beta-adrenergic system.

Authors:  E Davis; R Loiacono; R J Summers
Journal:  Br J Pharmacol       Date:  2008-06       Impact factor: 8.739

6.  Beneficial effect of albuterol in congenital myasthenic syndrome with epsilon-subunit mutations.

Authors:  Menachem Sadeh; Xin-Ming Shen; Andrew G Engel
Journal:  Muscle Nerve       Date:  2011-06-30       Impact factor: 3.217

7.  Muscular and cardiorespiratory effects of pseudoephedrine in human athletes.

Authors:  N D Gill; A Shield; A J Blazevich; S Zhou; R P Weatherby
Journal:  Br J Clin Pharmacol       Date:  2000-09       Impact factor: 4.335

Review 8.  Ephedrine for myasthenia gravis, neonatal myasthenia and the congenital myasthenic syndromes.

Authors:  Charlotte Vrinten; Angeli M van der Zwaag; Stephanie S Weinreich; Rob J P M Scholten; Jan J G M Verschuuren
Journal:  Cochrane Database Syst Rev       Date:  2014-12-17

Review 9.  Therapeutic strategies in congenital myasthenic syndromes.

Authors:  Ulrike Schara; Hanns Lochmüller
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

Review 10.  Adrenoceptors Modulate Cholinergic Synaptic Transmission at the Neuromuscular Junction.

Authors:  Ellya Bukharaeva; Venera Khuzakhmetova; Svetlana Dmitrieva; Andrei Tsentsevitsky
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.